PRINCETON, N.J., Nov. 12 EDDA Technology today announced the completion of CE mark for its new release of IQQA®-Liver, an advanced clinical application designed to enhance efficiency and precision in liver imaging evaluation and treatment planning.
IQQA®-Liver provides a comprehensive toolset for highly automated quantitative volumetric evaluation of liver, liver lobes and segments, hepatic lesions, and vascular structures including artery, portal veins and hepatic veins from CT data. Powered by innovative technologies, IQQA®-Liver facilitates physician's fast evaluation of imaging data as well as operative planning simulation of tumor resection and lobular/segmental/vascular separation/quantification/manipulation in real-time. Physicians may in real-time interactively adjust automated computer analysis results to achieve desired outcome typically within minutes.
IQQA®-Liver already has clearance by the FDA and China SFDA, and is currently used by radiologists and surgeons at numerous prestigious liver transplantation/surgery centers worldwide for pre- and post- operative assessment purposes, including University of Colorado Hospitals Denver, Shanghai Zhongshan Hospital, Tianjin First Center Hospital, Beijing You'an Hospital, and etc. Regulatory clearance of IQQA®-Liver in Taiwan is pending.
Through EDDA's proprietary IQQA® PACS- and web-enabling technology, IQQA®-Liver can be readily deployed onto any existing hospital PACS workstations or via the web so that data evaluation and treatment planning results can be shared quickly anywhere anytime among authorized physicians.
"Easy-to-use and easy-to-access advanced computer applications for fully quantitative analysis of organs are key to best utilizing the high resolution imaging information for precision treatment planning and post-surgical assessment," says Dr. Jian-Zhong Qian, President and CEO of EDDA Technology. "EDDA is committed to developing innovative technology and solutions to enhance the application of quantitative imaging to the entire healthcare cycle of patient management."
Liver disease is among the 10 major causes of death in the US according to the American Liver Foundation. Primary liver cancer, with approximately 1,000,000 cases reported every year in the world, is one of the most common malignancies. Many liver diseases can be potentially treated by surgery or transplantation. The liver is the second most commonly transplanted major organ after the kidney.
EDDA Technology will be exhibiting the IQQA® Family of Products in Booth #9318 at the 95th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), Nov. 29 - Dec. 3, 2009. Also featured is IQQA®-Chest Enterprise CAD (Computer Aided Detection) designed to assist physician's detection of small lung nodules from digital chest X-ray. The first prospective study on chest X-ray CAD published in peer-reviewed journal (Academic Radiology Vol. 15:5, pp. 571-575) demonstrated a significant sensitivity increase of physician's nodule detection from 63.8% without IQQA®-Chest to 92.7% with IQQA®-Chest assistance at University of Iowa's Carver College of Medicine.
About EDDA Technology
EDDA Technology, Inc. is an innovative clinical computer solution provider in diagnostic imaging and analysis. EDDA offers a series of new generation software products to enable early detection of diseases, and enhance efficiency and precision in diagnosis and treatment. EDDA's goal is to deliver, with broad accessibility, advanced information analysis technologies that improve clinical workflow and accuracy. A privately held Delaware corporation, EDDA is headquartered in Princeton, New Jersey, and has a subsidiary in Shanghai, China. IQQA® is a registered trademark of EDDA Technology. www.eddatech.com
SOURCE EDDA Technology, Inc.